ACBD4

Across TCGA pan-cancer cohorts, ACBD4 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ACBD4 data layer compared with 27 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ACBD4 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ACBD4 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and GBM are the cancer types where ACBD4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.833	0.414	.013	13	view →
PDAC	OS	Quartile	All	0.888	0.408	.012	12	view →
GBM	DFS	Quartile	All	0.472	0.184	.002	10	view →
LSCC	DFS	Median	II,III,IV	0.931	0.515	.023	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ACBD4–CCRCC (DFS)

Open the CCRCC breakdown →